Table 8.

Summary of ongoing trials for STKi for ovarian cancer.

Compound	Target	Study (NCT no.)	Phase	Country	Study start date	Status	Condition	Interventions
mTOR/AKT/PI3K pathway
Metformin	mTOR pathway	NCT01579812	Phase II	USA	10/2011	Recruiting	Advanced (primary treatment)	Met + chemotherapy
Metformin	mTOR pathway	NCT02437812	Phase II	USA	1/2014	Recruiting	Newly diagnosed (primary treatment)	Met + TC
Metformin	mTOR pathway	NCT02122185	Phase II	USA	6/2014	Recruiting	Stage III–IV (primary therapy)	TC (docetaxel) ± met (followed by met vs. placebo maintenance)
Metformin	mTOR pathway	NCT02312661	Phase I	Netherlands	10/2015	Recruiting	Recurrent	Met + TC
Everolimus	mTORC1	NCT01031381	Phase II	USA	9/2010	Completed 5/2013	Recurrent	Everolimus + bevacizumab
Everolimus	mTORC1	NCT01281514	Phase I	USA	12/2010	Recruiting	Platinum-sensitive recurrent	Everolimus + Carboplatin + PLD
Everolimus	mTORC1	NCT02188550	Phase II	USA	6/2014	Recruiting	Platinum-resistant or -refractory recurrent or persistent	Everolimus + letrozole
Everolimus	mTORC1	NCT02283658	Phase II	USA	11/2014	Ongoing Not recruiting	Recurrent hormone receptor positive	Everolimus Letrozole
Ridaforolimus	mTORC1	NCT01256268	Phase I	USA	6/2011	Ongoing Not recruiting	Recurrent or metastatic platinum-sensitive	Ridaforolimus + TC
Sirolimus	mTORC1	NCT01536054	Phase I	USA	8/2012	Ongoing Not recruiting	Recurrent	Sirolimus NY-ESO-1
Temsirolimus	mTORC1	NCT01065662	Phase I	USA	2/2010	Ongoing Not recruiting	Recurrent	Temsirolimus + cediranib
Temsirolimus	mTORC1	NCT01196429	Phase II	USA, Japan, Korea	8/2010	Completed (1/2015)	Stages III and IV OCCC (primary treatment)	Temsirolimus + TC (then temsirolimus consolidation)
Temsirolimus	mTORC1	NCT01460979	Phase II	Germany	10/2011	Completed (11/2015)	Platinum-refractory	Temsirolimus
GSK2141795	AKT	NCT01266954	Phase I	UK	6/2010	Completed (12/2014)a	Recurrent or persistent	GSK2141795
MK2206	AKT	NCT01283035	Phase II	USA	4/2011	Completed (12/2014)	Recurrent platinum-resistant	MK2206
GSK2110183	AKT	NCT01653912	Phase I/II	Australia, Russia, UK	12/2012	Ongoing Not recruiting	Recurrent platinum-resistant	GSK2110183 + TC
Triciribine	AKT	NCT01690468	Phase I/II	USA	9/2014	Ongoing Not recruiting	Recurrent or persistent platinum-resistant	Triciribine + carboplatin
COTI2	AKT	NCT02433626	Phase I	USA	12/2015	Recruiting	Recurrent platinum-resistant	COTI2
MAPK pathway
Sorafenib	MAPK	NCT00436215	Phase II	USA	9/2006	Completed (6/2014)	Recurrent platinum-resistant/refractory	Sorafenib + bevacizumab
Sorafenib	MAPK	NCT01047891	phase II	Germany	1/2010	Completed (2/2015)	Recurrent platinum-resistant	Sorafenib
Trametinib	MAPK	NCT02101788	Phase II/III	USA, UK	2/2014	Recruiting	Recurrent or progressive LGSOC	Trametinib vs. letrozole, paclitaxel, PLD, tamoxifen, or topotecan
LY2228820	MAPK	NCT01663857	Phase I/II	Multi-countriesc	9/2012	Recruiting	Recurrent platinum-sensitive	LY2228820 + gemcitabine + carboplatin
MEK 162	MEK	NCT01649336	Phase I	USA	7/2012	Ongoing Not recruiting	Platinum-resistant or -refractory	MEK 162 + paclitaxel
MEK 162	MEK	NCT01849874	Phase III	Multi-countriesd	6/2013	Recruiting	Recurrent, persistent, or progressive LGSOC	MEK 162 vs. PLD, paclitaxel, or topotecan
Aurora kinase pathway
Alisertib	Aurora kinase	NCT01091428	Phase I/II	USA	5/2010	Ongoing Not recruiting	Recurrent	Alisertib + paclitaxel
Multiple STKi
Pimasertib + SAR245409	MAPK, PI3K	NCT01936363	Phase II	Multi-countriesb	9/2013	Ongoing Not recruiting	Previously treated unresectable LGSOC	Pimasertib + SAR245409 vs. placebo

Table compiled through access to clinicaltrials.gov on 24 December 2015. Ongoing, recruiting, and completed studies involving only mullerian cancers are listed.

^aResults were available after our search on 24 September 2015.

^bUSA, Australia, Belgium, Canada, France, Italy, Poland, and Spain.

^cUSA, Australia, Belgium, Germany.

^dUSA, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Spain, Sweden, and the United Kingdom.

met: Metformin; TC: paclitaxel/carboplatin; PLD: pegylated liposomal doxorubicin; OCCC: ovarian clear cell carcinoma; LGSOC: low-grade serous ovarian carcinoma; STKi: STK inhibitor; STK: Serine–threonine kinases; mTOR: mammalian target of rapamycin; AKT: protein kinase B; PI3K: phosphatidylinositol 3-kinase; MAPK: mitogen-activated protein kinase; MEK: mitogen-activated protein kinase kinase.